The Adaptive Experience
Nearly half of all patients who receive clonoSEQ MRD testing are monitored more frequently than once per year.
When is clonoSEQ being used for patients with lymphoid cancers?
clonoSEQ testing frequency varies based on the clinical situation, yet nearly half of all clonoSEQ-tested patients are being monitored more than once per year. Many HCPs have noted the value they find in serial monitoring, as MRD results are often more informative when considered as a trend vs. a single point-in-time assessment.
ALL, MM, and CLL patients tested from June 2019 through Jun 2020 (MRD)
This page is intended for use by healthcare professionals of the United States.
clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technicalsummary.